IP Library Granted Patent US 8,202,874
Granted Patent B2
US 8,202,874 · App. 12/968,958 · Granted Jun 19, 2012

Substituted N-oxide pyrazine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,874
App. No.
12/968,958
Granted
Jun 19, 2012
Kind
B2
Abstract

N-oxide pyrazine derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: R1, R2, R3, R4, and R5 are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I) and their use in therapeutics.

Claims (25)

1. A compound of formula (I):

wherein:

R1 represents a 4-pyridine ring or a halogen atom;

R2 represents a hydrogen atom;

R3 represents a hydrogen atom;

R4 represents:

a phenylC 1-3 alkyl group, this group being optionally substituted by 1 to 4 substituents selected from a C 1-6 alkyl group, a halogen atom, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a hydroxyl group, a C 1-6 alkoxy group, a C 1-2 perhalogenated alkoxy group, a C 1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C 1-6 monoalkylamino group, a C 2-12 dialkylamino group, an acetoxy group, and an aminosulfonyl group; and

R5 represents a hydrogen atom;

or a pharmaceutically acceptable salt thereof.

2. The compound of formula (I) according to claim 1 :

wherein:

R1 represents a 4-pyridine ring or a halogen atom;

R2 represents a hydrogen atom;

R3 represents a hydrogen atom;

R4 represents: a phenylC 1-3 alkyl group, this group being optionally substituted by 1 to 4 substituents selected from a halogen atom and a hydroxyl group; and

R5 represents a hydrogen atom;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 selected from the group consisting of:

N-(2-phenylethyl)-6-pyridin-4-ylpyrazin-2-amine 4-oxide;

(+/−)2-[(4-oxido-6-pyridin-4-ylpyrazin-2-yl)amino]-1-phenylethanol;

(+/−)6-2-[(6-chloro-4-oxidopyrazin-2-yl)amino]-1-phenylethanol; and

6-chloro-N-(2-phenylethyl)pyrazin-2-amine 4-oxide.

4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutical additives.

5. A pharmaceutical composition comprising a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt thereof and one or more pharmaceutical additives.

6. A pharmaceutical composition comprising a compound according to claim 3 or a pharmaceutically acceptable salt thereof and one or more pharmaceutical additives.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2011
From: LOCHEAD, ALISTAIR; SAADY, MOURAD; YAICHE, PHILIPPE
To: SANOFI-AVENTIS; MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 026906/0067 →